Compass Therapeutics, Inc. CMPX
- CTX-8371 — Non-Small Cell Lung Cancer Phase 1
- CTX-8371 — Triple-Negative Breast Cancer Phase 1
- CTX-8371 — Hodgkin Lymphoma Phase 1
PD-L1 (9 companies · 13 programs)
Companies with an active program directed at PD-L1.
ImmunityBio, Inc. IBRX
- PD-L1 t-haNK — Triple-Negative Breast Cancer Phase 1
- PD-L1 t-haNK — Pancreatic Cancer Phase 2
- PD-L1 t-haNK — Glioblastoma Phase 1
Adagene Inc. ADAG
- ADG104 Phase 2
Aptevo Therapeutics Inc. APVO
- APVO711 Preclinical
BriaCell Therapeutics Corp. BCTX
- Soluble CD80 Preclinical
CRESCENT BIOPHARMA, INC. CBIO
- CR-002 Preclinical
EXELIXIS, INC. EXEL
- XB628 — Solid Tumors Phase 1
Fortress Biotech, Inc. FBIO
- UNLOXCYT — Cutaneous Squamous Cell Carcinoma Approved
NovaBridge Biosciences NBP
- ragistomig — Solid Tumors Phase 1